• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chest. Airway T Lymphocytes in Puumala Hantavirus Disease

Giuseppe

Emeritus
[Source: Chest, full text: (LINK). Abstract, edited.]

Airway T Lymphocytes in Puumala Hantavirus Disease



Rasmuson, J., Pourazar, J., Linderholm, M., Sandstrom, T., Blomberg, A., Ahlm, C.


Background:

Hantaviruses cause two clinical syndromes: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). The clinical spectrum in HFRS also often involves respiratory symptoms. As information about the pulmonary pathogenesis in HFRS is limited, we aimed to further study the local airway immune response in the lower airways.


Methods:

Bronchoscopy was performed in 15 hospitalized patients with HFRS, with sampling of endobronchial mucosal biopsies and BAL fluid. Biopsies were stained for leukocytes, lymphocyte subsets, and vascular endothelial adhesion molecules. BAL fluid and blood lymphocyte subsets were determined using flow cytometry. Fourteen healthy volunteers acted as a control group.


Results:

Compared with control subjects, endobronchial mucosal biopsies from patients with HFRS revealed increased numbers of CD8<SUP>+</SUP> T cells in both epithelium and submucosa (P ≤ .001), along with an increase in submucosal CD4<SUP>+</SUP> T cells (P = .001). In contrast, patients? submucosal neutrophil and eosinophil numbers were reduced (P < .001). The expression of vascular cell adhesion molecule-1 (VCAM-1) was enhanced in patients with HFRS (P < .001). In patients with HFRS, analyses of T-cell subsets in BAL fluid showed higher proportions of CD3<SUP>+</SUP> and CD8<SUP>+</SUP> T cells (P = .011 and P = .025) and natural killer cells (P < .001), together with an increased expression of activation markers human leukocyte antigen-DR (HLA-DR) and CD25 on T cells (P < .001 and P < .001).


Conclusions:
The present findings indicate a local immune response in terms of activated T lymphocytes in the lungs of patients with HFRS. The elevated expression of activation markers and VCAM-1 further implies the importance of cytotoxic lymphocytes in the pathogenesis of pulmonary involvement in HFRS.
- ------
 
Back
Top Bottom